{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:08:30Z","timestamp":1789672110879,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11030-024-10965-y","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T05:02:24Z","timestamp":1723698144000},"page":"2081-2098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gene network analysis combined with preclinical studies to identify and elucidate the mechanism of action of novel irreversible Keap1 inhibitor for Parkinson\u2019s disease"],"prefix":"10.1007","volume":"29","author":[{"given":"Monisha","family":"Arumugam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjith Sanjeeve","family":"Pachamuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emdormi","family":"Rymbai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya Prakash","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalirajan","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Kothandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhoshkumar","family":"Muthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divakar","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"10965_CR1","doi-asserted-by":"publisher","first-page":"9832839","DOI":"10.1155\/2016\/9832839","volume":"2016","author":"F Magrinelli","year":"2016","unstructured":"Magrinelli F, Picelli A, Tocco P, Federico A, Roncari L, Smania N, Zanette G, Tamburin S (2016) Pathophysiology of motor dysfunction in Parkinson\u2019s disease as the rationale for drug treatment and rehabilitation. Parkinsons Dis 2016:9832839. https:\/\/doi.org\/10.1155\/2016\/9832839","journal-title":"Parkinsons Dis"},{"key":"10965_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fnana.2017.00099","volume":"11","author":"Y Tang","year":"2017","unstructured":"Tang Y, Xiao X, Xie H, Wan CM, Meng L, Liu ZH, Liao WH, Tang BS, Guo JF (2017) Altered functional brain connectomes between sporadic and familial Parkinson\u2019s patients. Front Neuroanat 11:99. https:\/\/doi.org\/10.3389\/fnana.2017.00099","journal-title":"Front Neuroanat"},{"key":"10965_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41531-020-0110-8","volume":"6","author":"J Tran","year":"2020","unstructured":"Tran J, Anastacio H, Bardy C (2020) Genetic predispositions of Parkinson\u2019s disease revealed in patient-derived brain cells. NPJ Parkinsons Dis 6:8. https:\/\/doi.org\/10.1038\/s41531-020-0110-8","journal-title":"NPJ Parkinsons Dis"},{"key":"10965_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1749-6632.2003.tb07470.x","volume":"991","author":"MF Beal","year":"2003","unstructured":"Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson\u2019s disease. Ann N Y Acad Sci 991:120\u2013131. https:\/\/doi.org\/10.1111\/j.1749-6632.2003.tb07470.x","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10965_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13024-023-00630-7","volume":"18","author":"J Lee","year":"2023","unstructured":"Lee J, Sung KW, Bae EJ, Yoon D, Kim D, Lee JS, Park DH, Park DY, Mun SR, Kwon SC, Kim HY, Min JO, Lee SJ, Suh YH, Kwon YT (2023) Targeted degradation of \u237a-synuclein aggregates in Parkinson\u2019s disease using the AUTOTAC technology. Mol Neurodegener 18(1):41. https:\/\/doi.org\/10.1186\/s13024-023-00630-7","journal-title":"Mol Neurodegener"},{"key":"10965_CR6","doi-asserted-by":"publisher","first-page":"4318416","DOI":"10.1155\/2017\/4318416","volume":"2017","author":"CLDC Camp\u00ealo","year":"2017","unstructured":"Camp\u00ealo CLDC, Silva RH (2017) Genetic variants in SNCA and the risk of sporadic Parkinson\u2019s disease and clinical outcomes: a review. Parkinsons Dis 2017:4318416. https:\/\/doi.org\/10.1155\/2017\/4318416","journal-title":"Parkinsons Dis"},{"issue":"5321","key":"10965_CR7","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science 276(5321):2045\u20132047. https:\/\/doi.org\/10.1126\/science.276.5321.2045","journal-title":"Science"},{"issue":"2","key":"10965_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","volume":"46","author":"M Sharma","year":"2023","unstructured":"Sharma M, Burr\u00e9 J (2023) \u03b1-Synuclein in synaptic function and dysfunction. Trends Neurosci 46(2):153\u2013166. https:\/\/doi.org\/10.1016\/j.tins.2022.11.007","journal-title":"Trends Neurosci"},{"issue":"6","key":"10965_CR9","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1007\/s10571-023-01355-3","volume":"43","author":"E Brolin","year":"2023","unstructured":"Brolin E, Ingelsson M, Bergstr\u00f6m J, Erlandsson A (2023) Altered distribution of SNARE proteins in primary neurons exposed to different alpha-synuclein proteoforms. Cell Mol Neurobiol 43(6):3023\u20133035. https:\/\/doi.org\/10.1007\/s10571-023-01355-3","journal-title":"Cell Mol Neurobiol"},{"key":"10965_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105966","volume":"176","author":"J Estaun-Panzano","year":"2023","unstructured":"Estaun-Panzano J, Arotcarena ML, Bezard E (2023) Monitoring \u03b1-synuclein aggregation. Neurobiol Dis 176:105966. https:\/\/doi.org\/10.1016\/j.nbd.2022.105966","journal-title":"Neurobiol Dis"},{"issue":"9","key":"10965_CR11","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41593-022-01140-3","volume":"25","author":"ML Choi","year":"2022","unstructured":"Choi ML, Chappard A, Singh BP, Maclachlan C, Rodrigues M, Fedotova EI, Berezhnov AV, De S, Peddie CJ, Athauda D, Virdi GS, Zhang W, Evans JR, Wernick AI, Zanjani ZS, Angelova PR, Esteras N, Vinokurov AY, Morris K, Jeacock K, Tosatto L, Little D, Gissen P, Clarke DJ, Kunath T, Collinson L, Klenerman D, Abramov AY, Horrocks MH, Gandhi S (2022) Pathological structural conversion of \u03b1-synuclein at the mitochondria induces neuronal toxicity. Nat Neurosci 25(9):1134\u20131148. https:\/\/doi.org\/10.1038\/s41593-022-01140-3","journal-title":"Nat Neurosci"},{"issue":"1","key":"10965_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bpa.12344","volume":"27","author":"JH Power","year":"2017","unstructured":"Power JH, Barnes OL, Chegini F (2017) Lewy bodies and the mechanisms of neuronal cell death in Parkinson\u2019s disease and dementia with lewy bodies. Brain Pathol 27(1):3\u201312. https:\/\/doi.org\/10.1111\/bpa.12344","journal-title":"Brain Pathol"},{"issue":"2","key":"10965_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4161\/auto.8.2.18938","volume":"8","author":"D Ebrahimi-Fakhari","year":"2012","unstructured":"Ebrahimi-Fakhari D, McLean PJ, Unni VK (2012) Alpha-synuclein\u2019s degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy 8(2):281\u2013283. https:\/\/doi.org\/10.4161\/auto.8.2.18938","journal-title":"Autophagy"},{"key":"10965_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-1-0716-1495-2_10","volume":"2322","author":"H Maegawa","year":"2021","unstructured":"Maegawa H, Niwa H (2021) Generation of mitochondrial toxin rodent models of Parkinson\u2019s disease using 6-OHDA, MPTP, and rotenone. Methods Mol Biol 2322:95\u2013110. https:\/\/doi.org\/10.1007\/978-1-0716-1495-2_10","journal-title":"Methods Mol Biol"},{"key":"10965_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022","volume":"156","author":"A Chakkittukandiyil","year":"2022","unstructured":"Chakkittukandiyil A, Sajini DV, Karuppaiah A, Selvaraj D (2022) The principal molecular mechanisms behind the activation of Keap1\/Nrf2\/ARE pathway leading to neuroprotective action in Parkinson\u2019s disease. Neurochem Int 156:105325. https:\/\/doi.org\/10.1016\/j.neuint.2022","journal-title":"Neurochem Int"},{"key":"10965_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pharmthera.2015.11.003","volume":"157","author":"I Buendia","year":"2016","unstructured":"Buendia I, Michalska P, Navarro E, Gameiro I, Egea J, Le\u00f3n R (2016) Nrf2-ARE pathway: an emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. Pharmacol Ther 157:84\u2013104. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.11.003","journal-title":"Pharmacol Ther"},{"issue":"23","key":"10965_CR17","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.1128\/MCB.23.23.8786-8794.2003","volume":"23","author":"MK Kwak","year":"2003","unstructured":"Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW (2003) Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol 23(23):8786\u20138794. https:\/\/doi.org\/10.1128\/MCB.23.23.8786-8794.2003","journal-title":"Mol Cell Biol"},{"issue":"10","key":"10965_CR18","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1080\/15548627.2016.1208889","volume":"12","author":"M Pajares","year":"2016","unstructured":"Pajares M, Jim\u00e9nez-Moreno N, Garc\u00eda-Yag\u00fce \u00c1J, Escoll M, de Ceballos ML, Van Leuven F, R\u00e1bano A, Yamamoto M, Rojo AI, Cuadrado A (2016) Transcription factor NFE2L2\/NRF2 is a regulator of macroautophagy genes. Autophagy 12(10):1902\u20131916. https:\/\/doi.org\/10.1080\/15548627.2016.1208889","journal-title":"Autophagy"},{"key":"10965_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.dscb.2021.100019","volume":"3","author":"S Upadhayay","year":"2021","unstructured":"Upadhayay S, Mehan S (2021) Targeting Nrf2\/HO-1 anti-oxidant signaling pathway in the progression of multiple sclerosis and influences on neurological dysfunctions. Brain Disorders 3:100019. https:\/\/doi.org\/10.1016\/j.dscb.2021.100019","journal-title":"Brain Disorders"},{"key":"10965_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.prmcm.2022.100190","volume":"5","author":"S Singh","year":"2022","unstructured":"Singh S, Arthur R, Upadhayay S, Kumar P (2022) Ferulic acid ameliorates neurodegeneration via the Nrf2\/ARE signalling pathway: a review. Pharmacol Res-Modern Chin Med 5:100190. https:\/\/doi.org\/10.1016\/j.prmcm.2022.100190","journal-title":"Pharmacol Res-Modern Chin Med"},{"key":"10965_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.714370","volume":"9","author":"SA Sinenko","year":"2021","unstructured":"Sinenko SA, Starkova TY, Kuzmin AA, Tomilin AN (2021) Physiological signaling functions of reactive oxygen species in stem cells: from flies to man. Front Cell Dev Biol 9:714370. https:\/\/doi.org\/10.3389\/fcell.2021.714370","journal-title":"Front Cell Dev Biol"},{"issue":"22","key":"10965_CR22","doi-asserted-by":"publisher","first-page":"8137","DOI":"10.1128\/MCB.23.22.8137-8151.2003","volume":"23","author":"DD Zhang","year":"2003","unstructured":"Zhang DD, Hannink M (2003) Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 23(22):8137\u20138151. https:\/\/doi.org\/10.1128\/MCB.23.22.8137-8151.2003","journal-title":"Mol Cell Biol"},{"key":"10965_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.abb.2017.08.003","volume":"631","author":"A Bresciani","year":"2017","unstructured":"Bresciani A, Missineo A, Gallo M, Cerretani M, Fezzardi P, Tomei L, Cicero DO, Altamura S, Santoprete A, Ingenito R, Bianchi E, Pacifici R, Dominguez C, Munoz-Sanjuan I, Harper S, Toledo-Sherman L, Park LC (2017) Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1). Arch Biochem Biophys 631:31\u201341. https:\/\/doi.org\/10.1016\/j.abb.2017.08.003","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"10965_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038911","volume":"10","author":"T Payne","year":"2020","unstructured":"Payne T, Sassani M, Buckley E, Moll S, Anton A, Appleby M, Maru S, Taylor R, McNeill A, Hoggard N, Mazza C, Wilkinson ID, Jenkins T, Foltynie T, Bandmann O (2020) Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson\u2019s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The \u201cUP\u201d study. BMJ Open 10(8):e038911","journal-title":"BMJ Open"},{"issue":"3","key":"10965_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120254","volume":"10","author":"MS Brennan","year":"2015","unstructured":"Brennan MS, Matos MF, Li B, Hronowski X, Gao B, Juhasz P, Rhodes KJ, Scannevin RH (2015) Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. PLoS ONE 10(3):e0120254. https:\/\/doi.org\/10.1371\/journal.pone.0120254","journal-title":"PLoS ONE"},{"issue":"11","key":"10965_CR26","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.3390\/biomedicines10112929","volume":"10","author":"IU Rehman","year":"2022","unstructured":"Rehman IU, Khan A, Ahmad R, Choe K, Park HY, Lee HJ, Atiq A, Park J, Hahm JR, Kim MO (2022) Neuroprotective effects of nicotinamide against MPTP-Induced Parkinson\u2019s disease in mice: impact on oxidative stress, neuroinflammation, Nrf2\/HO-1 and TLR4 signaling pathways. Biomedicines 10(11):2929. https:\/\/doi.org\/10.3390\/biomedicines10112929","journal-title":"Biomedicines"},{"key":"10965_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116355","volume":"270","author":"G Culletta","year":"2024","unstructured":"Culletta G, Buttari B, Arese M, Brogi S, Almerico AM, Saso L, Tutone M (2024) Natural products as non-covalent and covalent modulators of the KEAP1\/NRF2 pathway exerting antioxidant effects. Eur J Med Chem 270:116355. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116355","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10965_CR28","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1021\/ci500175r","volume":"54","author":"D Toledo Warshaviak","year":"2014","unstructured":"Toledo Warshaviak D, Golan G, Borrelli KW, Zhu K, Kalid O (2014) Structure-based virtual screening approach for discovery of covalently bound ligands. J Chem Inf Model 54(7):1941\u20131950. https:\/\/doi.org\/10.1021\/ci500175r","journal-title":"J Chem Inf Model"},{"key":"10965_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2023.2258968","volume":"18","author":"A Chakkittukandiyil","year":"2023","unstructured":"Chakkittukandiyil A, Chakraborty S, Kothandan R, Rymbai E, Muthu SK, Vasu S, Sajini DV, Sugumar D, Mohammad ZB, Jayaram S, Rajagopal K, Ramachandran V, Selvaraj D (2023) Side effects based network construction and drug repositioning of ropinirole as a potential molecule for Alzheimer\u2019s disease: an in-silico, in-vitro, and in-vivo study. J Biomol Struct Dyn 18:1\u201315. https:\/\/doi.org\/10.1080\/07391102.2023.2258968","journal-title":"J Biomol Struct Dyn"},{"key":"10965_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122144","volume":"333","author":"E Rymbai","year":"2023","unstructured":"Rymbai E, Sugumar D, Chakkittukandiyil A, Kothandan R, Selvaraj J, Selvaraj D (2023) The identification of cianidanol as a selective estrogen receptor beta agonist and evaluation of its neuroprotective effects on Parkinson\u2019s disease models. Life Sci 333:122144. https:\/\/doi.org\/10.1016\/j.lfs.2023.122144","journal-title":"Life Sci"},{"key":"10965_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.631501","volume":"15","author":"Z Xu","year":"2021","unstructured":"Xu Z, Yang D, Huang X, Huang H (2021) Astragaloside IV protects 6-hydroxydopamine-induced SH-SY5Y cell model of Parkinson\u2019s disease via activating the JAK2\/STAT3 pathway. Front Neurosci 15:631501. https:\/\/doi.org\/10.3389\/fnins.2021.631501","journal-title":"Front Neurosci"},{"key":"10965_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.brainres.2015.02.006","volume":"1608","author":"Y Maddirala","year":"2015","unstructured":"Maddirala Y, Tobwala S, Ercal N (2015) N-acetylcysteineamide protects against manganese-induced toxicity in SHSY5Y cell line. Brain Res 1608:157\u2013166. https:\/\/doi.org\/10.1016\/j.brainres.2015.02.006","journal-title":"Brain Res"},{"issue":"7","key":"10965_CR33","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1074\/jbc.M603712200","volume":"282","author":"N Yamamoto","year":"2007","unstructured":"Yamamoto N, Sawada H, Izumi Y, Kume T, Katsuki H, Shimohama S, Akaike A (2007) Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem 282(7):4364\u20134372. https:\/\/doi.org\/10.1074\/jbc.M603712200","journal-title":"J Biol Chem"},{"key":"10965_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174112","volume":"903","author":"N Sharma","year":"2021","unstructured":"Sharma N, Khurana N, Muthuraman A, Utreja P (2021) Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson\u2019s disease rat model. Eur J Pharmacol 903:174112. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174112","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10965_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178008","volume":"12","author":"T Peng","year":"2017","unstructured":"Peng T, Ma L, Feng X, Tao J, Nan M, Liu Y, Li J, Shen L, Wu X, Yu R, Liu X, Qiu G, Zeng W (2017) Genomic and transcriptomic analyses reveal adaptation mechanisms of an Acidithiobacillus ferrivorans strain YL15 to alpine acid mine drainage. PLoS ONE 12(5):e0178008. https:\/\/doi.org\/10.1371\/journal.pone.0178008","journal-title":"PLoS ONE"},{"key":"10965_CR36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fphar.2020.00356","volume":"11","author":"M G\u00f3mez-Benito","year":"2020","unstructured":"G\u00f3mez-Benito M, Granado N, Garc\u00eda-Sanz P, Michel A, Dumoulin M, Moratalla R (2020) Modeling Parkinson\u2019s disease with the alpha-synuclein protein. Front Pharmacol 11:356. https:\/\/doi.org\/10.3389\/fphar.2020.00356","journal-title":"Front Pharmacol"},{"issue":"1","key":"10965_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/nen.0b013e31802d6da9","volume":"66","author":"CP Ramsey","year":"2007","unstructured":"Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66(1):75\u201385. https:\/\/doi.org\/10.1097\/nen.0b013e31802d6da9","journal-title":"J Neuropathol Exp Neurol"},{"key":"10965_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.arr.2018.06.003","volume":"7","author":"A Silva-Palacios","year":"2018","unstructured":"Silva-Palacios A, Ostolga-Chavarr\u00eda M, Zazueta C, K\u00f6nigsberg M (2018) Nrf2: molecular and epigenetic regulation during aging. Ageing Res Rev 7:31\u201340. https:\/\/doi.org\/10.1016\/j.arr.2018.06.003","journal-title":"Ageing Res Rev"},{"key":"10965_CR39","doi-asserted-by":"publisher","unstructured":"Lastres-Becker I, Garc\u00eda-Yag\u00fce AJ, Scannevin RH, Casarejos MJ, K\u00fcgler S, R\u00e1bano A, Cuadrado A (2016) Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's Disease. Antioxid Redox Signal 25(2):61\u201377. https:\/\/doi.org\/10.1089\/ars.2015.6549.","DOI":"10.1089\/ars.2015.6549"},{"key":"10965_CR40","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/npjparkd.2016.2","volume":"2","author":"LK Mischley","year":"2016","unstructured":"Mischley LK, Conley KE, Shankland EG, Kavanagh TJ, Rosenfeld ME, Duda JE, White CC, Wilbur TK, De La Torre PU, Padowski JM (2016) Central nervous system uptake of intranasal glutathione in Parkinson\u2019s disease. NPJ Parkinsons Dis 2:16002. https:\/\/doi.org\/10.1038\/npjparkd.2016.2","journal-title":"NPJ Parkinsons Dis"},{"key":"10965_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fnmol.2018.00236","volume":"11","author":"Z Wei","year":"2018","unstructured":"Wei Z, Li X, Li X, Liu Q, Cheng Y (2018) Oxidative stress in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Mol Neurosci 11:236. https:\/\/doi.org\/10.3389\/fnmol.2018.00236","journal-title":"Front Mol Neurosci"},{"key":"10965_CR42","doi-asserted-by":"publisher","first-page":"9372182","DOI":"10.1155\/2019\/9372182","volume":"2019","author":"N Robledinos-Ant\u00f3n","year":"2019","unstructured":"Robledinos-Ant\u00f3n N, Fern\u00e1ndez-Gin\u00e9s R, Manda G, Cuadrado A (2019) Activators and Inhibitors of NRF2: a review of their potential for clinical development. Oxid Med Cell Longev 2019:9372182. https:\/\/doi.org\/10.1155\/2019\/9372182","journal-title":"Oxid Med Cell Longev"},{"issue":"8","key":"10965_CR43","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1039\/d0md00154f","volume":"11","author":"F Sutanto","year":"2020","unstructured":"Sutanto F, Konstantinidou M, D\u00f6mling A (2020) Covalent inhibitors: a rational approach to drug discovery. RSC Med Chem 11(8):876\u2013884. https:\/\/doi.org\/10.1039\/d0md00154f","journal-title":"RSC Med Chem"},{"issue":"2","key":"10965_CR44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1128\/MCB.00868-15","volume":"36","author":"R Saito","year":"2015","unstructured":"Saito R, Suzuki T, Hiramoto K, Asami S, Naganuma E, Suda H, Iso T, Yamamoto H, Morita M, Baird L, Furusawa Y, Negishi T, Ichinose M, Yamamoto M (2015) Characterizations of three major cysteine sensors of Keap1 in stress response. Mol Cell Biol 36(2):271\u2013284. https:\/\/doi.org\/10.1128\/MCB.00868-15","journal-title":"Mol Cell Biol"},{"key":"10965_CR45","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.compbiolchem.2019.01.001","volume":"78","author":"V V\u00e9lez-Segarra","year":"2019","unstructured":"V\u00e9lez-Segarra V, Carrasquillo-Carri\u00f3n K, Santini-Gonz\u00e1lez JJ, Ramos-Valerio YA, V\u00e1zquez-Qui\u00f1ones LE, Roche-Lima A, Rodr\u00edguez-Medina JR, Par\u00e9s-Matos EI (2019) Modelling and molecular docking studies of the cytoplasmic domain of Wsc-family, full-length Ras2p, and therapeutic antifungal compounds. Comput Biol Chem 78:338\u2013352. https:\/\/doi.org\/10.1016\/j.compbiolchem.2019.01.001","journal-title":"Comput Biol Chem"},{"issue":"2","key":"10965_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1124\/molpharm.123.000671","volume":"104","author":"T Gatbonton-Schwager","year":"2023","unstructured":"Gatbonton-Schwager T, Yagishita Y, Joshi T, Wakabayashi N, Srinivasan H, Suzuki T, Yamamoto M, Kensler TW (2023) A point mutation at C151 of Keap1 of mice abrogates NRF2 signaling, cytoprotection in vitro, and hepatoprotection in vivo by bardoxolone methyl (CDDO-Me). Mol Pharmacol 104(2):51\u201361. https:\/\/doi.org\/10.1124\/molpharm.123.000671","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10965_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1089\/ars.2012.5118","volume":"19","author":"DD Zhang","year":"2013","unstructured":"Zhang DD (2013) Bardoxolone brings Nrf2-based therapies to light. Antioxid Redox Signal 19(5):517\u2013518. https:\/\/doi.org\/10.1089\/ars.2012.5118","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"10965_CR48","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1471-4159.2009.06552.x","volume":"112","author":"TG Son","year":"2010","unstructured":"Son TG, Camandola S, Arumugam TV, Cutler RG, Telljohann RS, Mughal MR, Moore TA, Luo W, Yu QS, Johnson DA, Johnson JA, Greig NH, Mattson MP (2010) Plumbagin, a novel Nrf2\/ARE activator, protects against cerebral ischemia. J Neurochem 112(5):1316\u20131326. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06552.x","journal-title":"J Neurochem"},{"issue":"7","key":"10965_CR49","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3390\/molecules23071803","volume":"23","author":"SM de Freitas","year":"2018","unstructured":"de Freitas SM, Pruccoli L, Morroni F, Sita G, Seghetti F, Viegas C, Tarozzi A (2018) The Keap1\/Nrf2-ARE pathway as a pharmacological target for chalcones. Molecules 23(7):1803. https:\/\/doi.org\/10.3390\/molecules23071803","journal-title":"Molecules"},{"issue":"1","key":"10965_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bcp.2013.12.022","volume":"88","author":"L Gambhir","year":"2014","unstructured":"Gambhir L, Checker R, Thoh M, Patwardhan RS, Sharma D, Kumar M, Sandur SK (2014) 1,4-Naphthoquinone, a pro-oxidant, suppresses immune responses via KEAP-1 glutathionylation. Biochem Pharmacol 88(1):95\u2013105. https:\/\/doi.org\/10.1016\/j.bcp.2013.12.022","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10965_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063862","volume":"8","author":"JA Korecka","year":"2013","unstructured":"Korecka JA, van Kesteren RE, Blaas E, Spitzer SO, Kamstra JH, Smit AB, Swaab DF, Verhaagen J, Bossers K (2013) Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS ONE 8(5):e63862. https:\/\/doi.org\/10.1371\/journal.pone.0063862","journal-title":"PLoS ONE"},{"key":"10965_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-7091-6842-4_7","volume":"50","author":"Y Glinka","year":"1997","unstructured":"Glinka Y, Gassen M, Youdim MB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 50:55\u201366. https:\/\/doi.org\/10.1007\/978-3-7091-6842-4_7","journal-title":"J Neural Transm Suppl"},{"key":"10965_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/680816","volume":"2013","author":"M Guida","year":"2013","unstructured":"Guida M, Maraldi T, Resca E, Beretti F, Zavatti M, Bertoni L, La Sala GB, De Pol A (2013) Inhibition of nuclear Nox4 activity by plumbagin: effect on proliferative capacity in human amniotic stem cells. Oxid Med Cell Longev 2013:680816. https:\/\/doi.org\/10.1155\/2013\/680816","journal-title":"Oxid Med Cell Longev"},{"key":"10965_CR54","doi-asserted-by":"publisher","first-page":"6940953","DOI":"10.1155\/2020\/6940953","volume":"2020","author":"Z Yin","year":"2020","unstructured":"Yin Z, Zhang J, Chen L, Guo Q, Yang B, Zhang W, Kang W (2020) Anticancer effects and mechanisms of action of plumbagin: review of research advances. Biomed Res Int 2020:6940953. https:\/\/doi.org\/10.1155\/2020\/6940953","journal-title":"Biomed Res Int"},{"key":"10965_CR55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.biopha.2016.05.007","volume":"82","author":"S Sameni","year":"2016","unstructured":"Sameni S, Hande MP (2016) Plumbagin triggers DNA damage response, telomere dysfunction and genome instability of human breast cancer cells. Biomed Pharmacother 82:256\u2013268. https:\/\/doi.org\/10.1016\/j.biopha.2016.05.007","journal-title":"Biomed Pharmacother"},{"key":"10965_CR56","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.redox.2013.08.006","volume":"1","author":"ML Steele","year":"2013","unstructured":"Steele ML, Fuller S, Patel M, Kersaitis C, Ooi L, M\u00fcnch G (2013) Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells. Redox Biol 1:441\u2013445. https:\/\/doi.org\/10.1016\/j.redox.2013.08.006","journal-title":"Redox Biol"},{"key":"10965_CR57","first-page":"273","volume":"70","author":"WJ Schmidt","year":"2006","unstructured":"Schmidt WJ, Alam M (2006) Controversies on new animal models of Parkinson\u2019s disease pro and con: the rotenone model of Parkinson\u2019s disease (PD). J Neural Transm Suppl 70:273\u2013276","journal-title":"J Neural Transm Suppl"},{"key":"10965_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105685","volume":"167","author":"SM Rocha","year":"2022","unstructured":"Rocha SM, Bantle CM, Aboellail T, Chatterjee D, Smeyne RJ, Tjalkens RB (2022) Rotenone induces regionally distinct \u03b1-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl\/6 mice. Neurobiol Dis 167:105685. https:\/\/doi.org\/10.1016\/j.nbd.2022.105685","journal-title":"Neurobiol Dis"},{"issue":"6","key":"10965_CR59","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3390\/molecules27061834","volume":"27","author":"M Kumar Arora","year":"2022","unstructured":"Kumar Arora M, Ratra A, Asdaq SMB, Alshamrani AA, Alsalman AJ, Kamal M, Tomar R, Sahoo J, Ashok J, Imran M (2022) Plumbagin alleviates intracerebroventricular-quinolinic acid induced depression-like behavior and memory deficits in wistar rats. Molecules 27(6):1834. https:\/\/doi.org\/10.3390\/molecules27061834","journal-title":"Molecules"},{"issue":"4","key":"10965_CR60","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.pharep.2017.02.006","volume":"69","author":"V Arruri","year":"2017","unstructured":"Arruri V, Komirishetty P, Areti A, Dungavath SKN, Kumar A (2017) Nrf2 and NF-\u03baB modulation by Plumbagin attenuates functional, behavioural and biochemical deficits in rat model of neuropathic pain. Pharmacol Rep 69(4):625\u2013632. https:\/\/doi.org\/10.1016\/j.pharep.2017.02.006","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10965_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40360-016-0094-5","volume":"17","author":"W Sumsakul","year":"2016","unstructured":"Sumsakul W, Plengsuriyakarn T, Na-Bangchang K (2016) Pharmacokinetics, toxicity, and cytochrome P450 modulatory activity of plumbagin. BMC Pharmacol Toxicol 17(1):50. https:\/\/doi.org\/10.1186\/s40360-016-0094-5","journal-title":"BMC Pharmacol Toxicol"},{"key":"10965_CR62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.biopha.2018.02.052","volume":"101","author":"KT Nakhate","year":"2018","unstructured":"Nakhate KT, Bharne AP, Verma VS, Aru DN, Kokare DM (2018) Plumbagin ameliorates memory dysfunction in streptozotocin induced Alzheimer\u2019s disease via activation of Nrf2\/ARE pathway and inhibition of \u03b2-secretase. Biomed Pharmacother 101:379\u2013390. https:\/\/doi.org\/10.1016\/j.biopha.2018.02.052","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10965_CR63","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/life13061303","volume":"13","author":"G Petrocelli","year":"2023","unstructured":"Petrocelli G, Marrazzo P, Bonsi L, Facchin F, Alviano F, Canaider S (2023) Plumbagin, a natural compound with several biological effects and anti-inflammatory properties. Life (Basel) 13(6):1303. https:\/\/doi.org\/10.3390\/life13061303","journal-title":"Life (Basel)"},{"key":"10965_CR64","doi-asserted-by":"publisher","first-page":"1837278","DOI":"10.1155\/2022\/1837278","volume":"2022","author":"Y Su","year":"2022","unstructured":"Su Y, Li M, Wang Q, Xu X, Qin P, Huang H, Zhang Y, Zhou Y, Yan J (2022) Inhibition of the TLR\/NF-\u03baB signaling pathway and improvement of autophagy mediates neuroprotective effects of plumbagin in Parkinson\u2019s disease. Oxid Med Cell Longev 2022:1837278. https:\/\/doi.org\/10.1155\/2022\/1837278","journal-title":"Oxid Med Cell Longev"},{"key":"10965_CR65","doi-asserted-by":"publisher","unstructured":"Chandran U, Mehendale N, Patil S, Chaguturu R, Patwardhan B (2017) Network pharmacology. Innovative Approaches Drug Discovery, pp 127\u201364. https:\/\/doi.org\/10.1016\/B978-0-12-801814-9.00005-2.","DOI":"10.1016\/B978-0-12-801814-9.00005-2"},{"issue":"5","key":"10965_CR66","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.pharep.2015.03.001","volume":"67","author":"D Dhingra","year":"2015","unstructured":"Dhingra D, Bansal S (2015) Antidepressant-like activity of plumbagin in unstressed and stressed mice. Pharmacol Rep 67(5):1024\u20131032. https:\/\/doi.org\/10.1016\/j.pharep.2015.03.001","journal-title":"Pharmacol Rep"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10965-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-10965-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10965-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T08:21:28Z","timestamp":1747297288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-10965-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10965"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-10965-y","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}